[Trabectedin (Yondelis) for the treatment of ovarian cancer]
Comite d'Avaluacio de Medicaments d'Utilitzacio Hospitalaria (CAMUH)
Record ID 32011000228
Spanish
Authors' objectives:
To review the available scientific evidence on the efficacy, safety and efficacy of trabectedin in combination with PLD in patients with platinum-sensitive relapsed ovarian cancer.
Authors' recommendations:
The greatest benefits of trabectedin in relapsed ovarian cancer are observed in partially platinum- sensitive patients in whom an improvement in progression-free survival has been observed when therapy is combined with PLD. The combination is generally well tolerated but it has been related to a higher rate of severe haematological and cardiac adverse events than PLD therapy alone.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.gencat.cat/salut/depsan/units/aatrm/pdf/trabectedina_cancer_ovari_aiaqs2011ca.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Antineoplastic Agents, Alkylating
- Ovarian Neoplasms
- Spain
- Tetrahydroisoquinolines
Contact
Organisation Name:
Agencia de Qualitat i Avaluacio Sanitries de Catalunya
Contact Address:
Antoni Parada, CAHTA, Roc Boronat, 81-95 (2nd floor), 08005 Barcelona, Spain, Tel. +34 935 513 928, Fax: +34 935 517 510
Contact Name:
direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Contact Email:
direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Copyright:
Catalan Agency for Health Information, Assessment and Quality (CAHIAQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.